VALOR is the largest interventional dermatomyositis study ever conducted. Double-blind placebo-controlled study enrolled 241 subjects randomized 1:1:1 to brepocitinib 30 mg, brepocitinib 15 mg, and placebo. Data are expected in the second half of 2025, with potential dermatomyositis NDA…